The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

HDAC抑制剂SB939可克服慢性粒细胞白血病中由BIM缺失多态性引起的对BCR-ABL激酶抑制剂的耐药性。